Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eloxatin oxaliplatin: Phase III data

In an international Phase III trial in 2,246 patients who had

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE